Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for a variety of hematologic diseases. However, this therapeutic platform is limited by an initial period when patients are profoundly immunocompromised. There is gradual immune recovery over time, that vari...
Main Authors: | Hany Elmariah, Claudio G. Brunstein, Nelli Bejanyan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/11/2/102 |
Similar Items
-
Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
by: Samuel Cytryn, et al.
Published: (2020-04-01) -
Improving engraftment and immune reconstitution in umbilical cord blood transplantation
by: Robert eDanby, et al.
Published: (2014-02-01) -
Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape
by: Carla Dessels, et al.
Published: (2018-09-01) -
Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
by: Lixin Xu, et al.
Published: (2018-03-01) -
Alternative Donor Transplantation for Acute Myeloid Leukemia
by: Nelli Bejanyan, et al.
Published: (2015-06-01)